• Palonosetron hydrochloride Research Workflows

  2026-08-12

  Build reproducible 5-HT3 receptor antagonist assays around nanomolar Palonosetron hydrochloride activity, then extend the workflow to transporter studies and translational oncology. This guide connects dual-site receptor pharmacology with practical concentration planning, controls, troubleshooting, and CINV/RINV research design.

• Cyclic di-GMP: From Biofilm Persistence to STING

  2026-08-12

  Cyclic di-GMP is more than a bacterial signaling metabolite: recent evidence positions this intracellular second messenger as a small-molecule antitoxin that shapes genome stability and antibiotic persistence in biofilms. This article translates that mechanism into a practical research strategy spanning biofilm formation regulation, STING-centered immune modulation research, and carefully bounded cancer immunotherapy studies.

• Tacalcitol monohydrate: Applied Research Workflows

  2026-08-11

  Tacalcitol monohydrate supports a practical VDR-centered workflow spanning keratinocyte NGF assays, dermatology models, and colorectal cancer research. Its defined concentration ranges, transcriptional readouts, and compatibility with 5-fluorouracil enable mechanism-led experiments rather than single-endpoint screening.

• 5-HT2C/1A Control DOM Biphasic Behaviors

  2026-08-11

  This 2024 Psychopharmacology study shows that DOM-induced head twitching and locomotor activity share 5-HT2A dependence but are shaped differently by 5-HT2C and 5-HT1A receptors at higher doses. Its pharmacological design separates the mechanisms underlying two inverted U-shaped behavioral responses and highlights Gαi/o signaling as an additional modulatory pathway.

• Anti Reverse Cap Analog for hiPSC mRNA Workflows

  2026-08-10

  Anti Reverse Cap Analog supports orientation-controlled synthetic mRNA capping for higher translation output in demanding cell-engineering workflows. This article connects practical ARCA-based in vitro transcription with the six-day OLIG2 mRNA differentiation strategy used to generate oligodendrocyte progenitors from hiPSCs.

• 5-Methyl-CTP for Reliable mRNA Synthesis

  2026-08-09

  Build more informative mRNA experiments by testing 5-Methyl-CTP as a controlled cytidine-triphosphate substitution rather than treating modification as a binary choice. This article connects transcript production, stability testing, translation assays, and vaccine-oriented development while separating product capabilities from evidence generated in an H5N1 dairy-cow study.

• GKT137831: Dual Nox1/Nox4 Inhibitor Workflows

  2026-08-08

  GKT137831 provides a source-directed way to study Nox1/Nox4-driven oxidative stress rather than applying a nonspecific antioxidant. This guide translates its vascular, fibrotic, and metabolic research applications into practical cell and animal workflows while showing how the compound can support, but not replace, emerging ferroptosis assays.

• Abiraterone acetate in 3D Prostate Cancer Assays

  2026-08-07

  Learn how to deploy Abiraterone acetate as a CYP17 inhibitor in patient-derived prostate cancer spheroids, from solvent handling to orthogonal readouts. The workflow separates compound-specific biology from model-specific limitations, helping researchers interpret androgen receptor activity inhibition in both 2D and 3D systems.

• Ibuprofen as an Anti-Proliferative Agent: Mechanistic Depth

  2026-08-07

  Explore how Ibuprofen (2-[4-(2-methylpropyl)phenyl]propanoic acid) advances colon cancer research as an anti-proliferative agent. This article uniquely connects molecular pharmacology, protocol optimization, and protein interaction insights for the discerning biomedical scientist.

• BRD4770: G9a Histone Methyltransferase Inhibitor for Advance

  2026-08-06

  BRD4770 delivers targeted, reproducible inhibition of G9a-mediated H3K9 methylation, enabling direct investigation of epigenetic regulation and tumorigenesis. This article translates bench protocols, troubleshooting insights, and comparative applications for BRD4770, empowering researchers to drive discoveries in cancer biology.

• Saracatinib (AZD0530): Decoding Src/Abl Inhibition in Comple

  2026-08-06

  Explore how Saracatinib (AZD0530) advances cancer biology through multi-pathway Src/Abl inhibition and precise modulation of cell proliferation and migration. This article delivers new insight for experimental design and translational research.

• Network Meta-Analysis: Azilsartan Medoxomil in Hypertension

  2026-08-05

  A recent systematic review and network meta-analysis rigorously compared azilsartan medoxomil (TAK 491) to other antihypertensive drugs in patients with mild-to-moderate hypertension. The study found that azilsartan medoxomil 80 mg demonstrated the highest probability of achieving superior blood pressure reduction among all evaluated treatments, offering evidence-backed guidance for future essential hypertension research.

• Salmonella-Derived Haem Suppresses Macrophage Phagocytosis

  2026-08-05

  This study uncovers a bacterial strategy wherein Salmonella upregulates its own haem biosynthesis—via a methyltransferase-mediated modification—to inhibit macrophage phagocytosis and enhance virulence in mice. The findings reveal an unexpected immune evasion mechanism with significant implications for infection biology and the modeling of heme pathway dynamics.

• Sulfachloropyridazine: Precision Antibacterial Tool for Fola

  2026-08-04

  Explore Sulfachloropyridazine, a potent sulfonamide antibacterial agent, through the lens of advanced mechanism, assay design, and real-world microbiome modeling. This article uniquely analyzes translational insights and protocol optimization for researchers.

• Fenofibrate: Age-Independent PPARα-YAP Insights for Translat

  2026-08-04

  Explore how Fenofibrate, a potent PPARα agonist, unlocks reproducible, age-independent activation of the PPARα-YAP pathway for advanced lipid metabolism and cancer biology research. This thought-leadership article connects mechanistic underpinnings, experimental best practices, and translational strategy—bridging bench discovery with clinical relevance and highlighting APExBIO's product leadership.

699 records 11/47 page Previous Next First page 上5页 1112131415 下5页 Last page